Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium

Trial Profile

Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Mepolizumab (Primary) ; Omalizumab (Primary)
  • Indications Allergic asthma; Eosinophilia
  • Focus Therapeutic Use
  • Acronyms PREDICTUMAB
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top